These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

298 related items for PubMed ID: 9660038

  • 1. Phase I clinical trial: pharmacokinetics of a novel anthracycline, DA-125 and metabolites. Single dose study.
    Roh JK, Rha SY, Lee CI, Lee KH, Lee JJ, Shim HJ, Lee SD, Kim WB, Yang J, Kim SH, Lee MG.
    Int J Clin Pharmacol Ther; 1998 Jun; 36(6):312-9. PubMed ID: 9660038
    [Abstract] [Full Text] [Related]

  • 2. Phase I-II trial of high-dose epirubicin in patients with lymphoma.
    Case DC, Gams R, Ervin TJ, Boyd MA, Oldham FB.
    Cancer Res; 1987 Dec 01; 47(23):6393-6. PubMed ID: 3479245
    [Abstract] [Full Text] [Related]

  • 3. Comparison of pharmacokinetics of M1, M2, M3, and M4 after intravenous administration of DA-125 or ME2303 to mice and rats. New adriamycin analogues containing fluorine.
    Yoon EJ, Lee WI, Shim HJ, Lee SD, Kim WB, Yang J, Lee MG.
    Biopharm Drug Dispos; 1996 Jul 01; 17(5):373-420. PubMed ID: 8830976
    [Abstract] [Full Text] [Related]

  • 4. Phase I clinical trial of pyrazoloacridine NSC366140 (PD115934).
    LoRusso P, Foster BJ, Poplin E, McCormick J, Kraut M, Flaherty L, Heilbrun LK, Valdivieso M, Baker L.
    Clin Cancer Res; 1995 Dec 01; 1(12):1487-93. PubMed ID: 9815948
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Initial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes).
    Cowens JW, Creaven PJ, Greco WR, Brenner DE, Tung Y, Ostro M, Pilkiewicz F, Ginsberg R, Petrelli N.
    Cancer Res; 1993 Jun 15; 53(12):2796-802. PubMed ID: 8504422
    [Abstract] [Full Text] [Related]

  • 8. Phase I clinical and pharmacokinetic trial of Brequinar sodium (DuP 785; NSC 368390).
    Arteaga CL, Brown TD, Kuhn JG, Shen HS, O'Rourke TJ, Beougher K, Brentzel HJ, Von Hoff DD, Weiss GR.
    Cancer Res; 1989 Aug 15; 49(16):4648-53. PubMed ID: 2743343
    [Abstract] [Full Text] [Related]

  • 9. Phase I and pharmacological study of single paclitaxel administered weekly for heavily pre-treated patients with epithelial ovarian cancer.
    Takano M, Kikuchi Y, Kita T, Suzuki M, Ohwada M, Yamamoto T, Yamamoto K, Inoue H, Shimizu K.
    Anticancer Res; 2002 Aug 15; 22(3):1833-8. PubMed ID: 12168878
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456).
    Vogelzang NJ, Mick R, Janisch L, Berezin F, Schilsky RL, Ratain MJ.
    Cancer Res; 1994 Jan 01; 54(1):114-9. PubMed ID: 8261430
    [Abstract] [Full Text] [Related]

  • 12. Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive days.
    Wolff I, Bench K, Beijnen JH, Bruntsch U, Cavalli F, de Jong J, Groot Y, van Tellingen O, Wanders J, Sessa C.
    Clin Cancer Res; 1996 Oct 01; 2(10):1717-23. PubMed ID: 9816122
    [Abstract] [Full Text] [Related]

  • 13. Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors.
    Supko JG, Balcerzak SP, Kraut EH.
    Cancer Res; 1993 Oct 15; 53(20):4843-9. PubMed ID: 8402671
    [Abstract] [Full Text] [Related]

  • 14. A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors.
    Hurwitz HI, Cohen RB, McGovren JP, Hirawat S, Petros WP, Natsumeda Y, Yoshinari T.
    Cancer Chemother Pharmacol; 2007 Jan 15; 59(1):139-47. PubMed ID: 16819636
    [Abstract] [Full Text] [Related]

  • 15. Phase I trial of orally administered pentosan polysulfate in patients with advanced cancer.
    Marshall JL, Wellstein A, Rae J, DeLap RJ, Phipps K, Hanfelt J, Yunmbam MK, Sun JX, Duchin KL, Hawkins MJ.
    Clin Cancer Res; 1997 Dec 15; 3(12 Pt 1):2347-54. PubMed ID: 9815633
    [Abstract] [Full Text] [Related]

  • 16. Phase I trial of intravenous carboplatin and cyclosporin A in refractory gynecologic cancer patients.
    Chambers SK, Davis CA, Chambers JT, Schwartz PE, Lorber MI, Hschumacher RE.
    Clin Cancer Res; 1996 Oct 15; 2(10):1699-704. PubMed ID: 9816119
    [Abstract] [Full Text] [Related]

  • 17. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.
    Trocòniz IF, Garrido MJ, Segura C, Cendrós JM, Principe P, Peraire C, Obach R.
    Cancer Chemother Pharmacol; 2006 Jun 15; 57(6):727-35. PubMed ID: 16261364
    [Abstract] [Full Text] [Related]

  • 18. Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer.
    Steinberg M.
    Clin Ther; 2008 Sep 15; 30(9):1590-617. PubMed ID: 18840366
    [Abstract] [Full Text] [Related]

  • 19. Phase II study of oral topotecan in advanced non-small cell lung cancer.
    White SC, Cheeseman S, Thatcher N, Anderson H, Carrington B, Hearn S, Ross G, Ranson M.
    Clin Cancer Res; 2000 Mar 15; 6(3):868-73. PubMed ID: 10741709
    [Abstract] [Full Text] [Related]

  • 20. Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancer.
    D'Andrea G, Fennelly D, Norton L, Baselga J, Gilewski T, Hudis C, Moynahan ME, Raptis G, Sklarin N, Surbone A, Theodoulou M, Templeton MA, Yao TJ, Seidman AD.
    Clin Cancer Res; 1999 Feb 15; 5(2):275-9. PubMed ID: 10037175
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.